BioSig Technologies, Inc.

Introduction

This page provides a comprehensive analysis of the known insider trading history of Fischer Seth H. Z.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Fischer Seth H. Z. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ESPR / Esperion Therapeutics, Inc. Director 61,150
US:MRNS / Marinus Pharmaceuticals, Inc. Director 0
US:AGRX / Agile Therapeutics, Inc. Director 0
US:SPPI / Spectrum Pharmaceuticals, Inc. Director 0
US:BSGM / BioSig Technologies, Inc. Director 60,000
US:928551AA8 / VIVUS, Inc. Bond 633,978
US:TSRX / Trius Therapeutics Inc Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Fischer Seth H. Z.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases BSGM / BioSig Technologies, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BSGM / BioSig Technologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BSGM / BioSig Technologies, Inc. Insider Trades
Insider Sales BSGM / BioSig Technologies, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BSGM / BioSig Technologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

BSGM / BioSig Technologies, Inc. Insider Trades
Insider Purchases ESPR / Esperion Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in BSGM / BioSig Technologies, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ESPR / Esperion Therapeutics, Inc. Insider Trades
Insider Sales ESPR / Esperion Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in BSGM / BioSig Technologies, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ESPR / Esperion Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Fischer Seth H. Z. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-02 2025-05-29 4 ESPR Esperion Therapeutics, Inc.
Common Stock
A - Award 33,000 61,150 117.23
2025-02-11 2025-02-11 4 MRNS MARINUS PHARMACEUTICALS, INC.
Common Stock
D - Sale to Issuer -2,300 0 -100.00 0.55 -1,265
2025-02-11 2025-02-07 4 MRNS MARINUS PHARMACEUTICALS, INC.
Common Stock
D - Sale to Issuer -12,707 2,300 -84.67 0.55 -6,989 1,265
2024-08-26 2024-08-26 4 AGRX AGILE THERAPEUTICS INC
Common Stock
D - Sale to Issuer -976 0 -100.00 1.52 -1,484
2024-06-20 2024-06-18 4 MRNS MARINUS PHARMACEUTICALS, INC.
Common Stock
A - Award 2,300 12,926 21.65
2024-05-24 2024-05-23 4 ESPR Esperion Therapeutics, Inc.
Common Stock
A - Award 23,000 28,150 446.60
2024-01-19 2024-01-18 4 MRNS MARINUS PHARMACEUTICALS, INC.
Common Stock
A - Award 4,600 10,626 76.34
2023-08-01 2023-07-31 4 SPPI SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
D - Sale to Issuer -54,066 0 -100.00
2023-06-16 2023-06-15 4 ESPR Esperion Therapeutics, Inc.
Common Stock
A - Award 5,150 5,150
2023-06-09 2023-06-08 4 AGRX AGILE THERAPEUTICS INC
Common Stock
A - Award 935 976 2,280.49
2023-02-08 2023-02-06 4 MRNS MARINUS PHARMACEUTICALS, INC.
Common Stock
S - Sale X -1,018 6,026 -14.45 6.54 -6,658 39,410
2023-01-30 2023-01-26 4 MRNS MARINUS PHARMACEUTICALS, INC.
Common Stock
A - Award 3,600 7,044 104.53
2022-09-02 2022-08-31 4 SPPI SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
A - Award 25,000 54,066 86.01
2022-06-22 2022-06-21 4 SPPI SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
S - Sale X -5,711 29,066 -16.42 0.78 -4,483 22,817
2022-06-10 2022-06-09 4 AGRX AGILE THERAPEUTICS INC
Common Stock
A - Award 670 2,066 47.99
2022-05-27 2022-05-26 4 ESPR Esperion Therapeutics, Inc.
Stock Option (right to buy
A - Award 11,561 11,561
2022-02-07 2022-02-04 4 MRNS MARINUS PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 12,375 12,375
2022-02-07 2022-02-04 4 MRNS MARINUS PHARMACEUTICALS INC
Common Stock
A - Award 2,750 3,444 396.25
2021-06-22 2021-06-18 4 SPPI SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
S - Sale X -12,000 34,777 -25.65 4.24 -50,880 147,454
2021-06-22 2021-06-17 4 SPPI SPECTRUM PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 67,804 67,804
2021-06-22 2021-06-17 4 SPPI SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
A - Award 14,277 46,777 43.93
2021-06-10 2021-06-08 4 AGRX AGILE THERAPEUTICS INC
Employee Stock Option (Right to Buy)
A - Award 29,905 29,905
2021-06-10 2021-06-08 4 AGRX AGILE THERAPEUTICS INC
Common Stock
A - Award 24,510 55,852 78.20
2021-01-19 2021-01-15 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 16,500 16,500
2020-06-19 2020-06-18 4 SPPI SPECTRUM PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 60,000 60,000
2020-06-19 2020-06-18 4 SPPI SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
A - Award 30,000 32,500 1,200.00
2020-06-11 2020-06-09 4 AGRX AGILE THERAPEUTICS INC
Employee Stock Option (Right to Buy)
A - Award 22,606 22,606
2020-06-11 2020-06-09 4 AGRX AGILE THERAPEUTICS INC
Common Stock
A - Award 13,393 31,342 74.62
2020-04-27 2020-04-23 4 SPPI SPECTRUM PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 5,000 5,000
2020-04-27 2020-04-23 4 SPPI SPECTRUM PHARMACEUTICALS INC
Common Stock, $0.001 par value
A - Award 2,500 2,500
2020-01-10 2020-01-08 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 100,000 100,000
2019-06-07 2019-06-06 4 AGRX AGILE THERAPEUTICS INC
Employee Stock Option (Right to Buy)
A - Award 75,000 75,000
2019-02-28 2019-02-26 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 35,000 35,000
2018-11-09 2018-10-16 4 BSGM BioSig Technologies, Inc.
Common Stock
A - Award 50,000 60,000 500.00
2018-06-08 2018-06-08 4 AGRX AGILE THERAPEUTICS INC
Restricted Stock Units
M - Exercise -17,949 0 -100.00
2018-06-08 2018-06-08 4 AGRX AGILE THERAPEUTICS INC
Common Stock
M - Exercise 17,949 17,949
2018-06-08 2018-06-07 4 AGRX AGILE THERAPEUTICS INC
Employee Stock Option (Right to Buy)
A - Award 50,000 50,000
2018-01-03 2018-01-01 4 VVUS VIVUS INC
Common Stock
D - Sale to Issuer -2,102 633,978 -0.33 0.50 -1,051 316,989
2017-12-08 2017-12-06 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 35,000 35,000
2017-06-09 2017-06-08 4 AGRX AGILE THERAPEUTICS INC
Restricted Stock Units
A - Award 17,949 17,949
2017-06-09 2017-06-08 4 AGRX AGILE THERAPEUTICS INC
Employee Stock Option (Right to Buy)
A - Award 14,000 14,000
2017-01-31 2017-01-27 4 VVUS VIVUS INC
Employee Stock Option (right to buy)
A - Award 1,000,000 1,000,000
2017-01-31 2017-01-27 4 VVUS VIVUS INC
Common Stock
A - Award 150,000 636,080 30.86
2017-01-19 2017-01-17 4 MRNS MARINUS PHARMACEUTICALS INC
Restricted stock
A - Award 4,500 4,500
2017-01-19 2017-01-17 4 MRNS MARINUS PHARMACEUTICALS INC
Stock option (right to buy)
A - Award 10,500 10,500
2016-09-28 2016-09-26 4 VVUS VIVUS INC
Common Stock
A - Award 300,000 486,080 161.22
2016-09-28 2016-01-22 4/A VVUS VIVUS INC
Employee Stock Option (right to buy)
A - Award 1,000,000 1,000,000
2016-09-07 3 MRNS MARINUS PHARMACEUTICALS INC
Restricted stock
13,200
2016-09-07 3 MRNS MARINUS PHARMACEUTICALS INC
Restricted stock
13,200
2016-07-28 2016-07-28 4 AGRX AGILE THERAPEUTICS INC
Employee Stock Option (Right to Buy)
A - Award 21,000 21,000
2016-01-26 2016-01-22 4 VVUS VIVUS INC
Employee Stock Option (right to buy)
A - Award 1,900,000 1,900,000
2015-08-05 2015-08-03 4 VVUS VIVUS INC
Common Stock
A - Award 117,000 186,080 169.37
2015-07-20 3 BSGM BioSig Technologies, Inc.
Common Stock, $0.001 par value per share
50,000
2015-07-20 3 BSGM BioSig Technologies, Inc.
Common Stock, $0.001 par value per share
50,000
2015-01-27 2015-01-23 4 VVUS VIVUS INC
Employee Stock Option (right to buy)
A - Award 628,600 628,600
2015-01-27 2015-01-23 4 VVUS VIVUS INC
Common Stock
A - Award 66,000 69,080 2,142.86
2014-03-12 2014-03-11 4 VVUS VIVUS INC
Common Stock
P - Purchase 3,080 3,080 6.07 18,695 18,695
2013-09-13 2013-09-11 4 TSRX Trius Therapeutics Inc
Stock Option (right to buy)
D - Sale to Issuer -2,500 0 -100.00 5.73 -14,325
2013-09-13 2013-09-11 4 TSRX Trius Therapeutics Inc
Stock Option (right to buy)
D - Sale to Issuer -30,000 0 -100.00 6.99 -209,700
2013-09-05 2013-09-03 4 VVUS VIVUS INC
Incentive Stock Option (right to buy)
A - Award 1,000,000 1,000,000
2013-05-23 2013-05-21 4 TSRX Trius Therapeutics Inc
Stock Option (right to buy)
A - Award 2,500 2,500
2013-04-04 2013-04-03 4 TSRX Trius Therapeutics Inc
Stock Option (right to buy)
A - Award 30,000 30,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)